Demographic and health factors associated with enrollment in posttrial studies: The women’s health initiative hormone therapy trials

Abstract

Background

After clinical trials end, continued follow-up of the assembled cohort often is desirable for additional research. Factors influencing participants’ decisions to consent to additional follow-up and how these shape posttrial cohorts have not been broadly studied.

Purpose

We examined how two re-enrollment campaigns and the passage of time altered features of the posttrial cohorts compared with the original Women’s Health Initiative (WHI) Hormone Therapy clinical trials.

Methods

We examined associations that markers of sociodemography, health, lifestyle, and on-trial experiences had with re-enrollment and contrasted the characteristics of successive posttrial cohorts with those of the original enrollees.

Results

The posttrial enrollment campaigns re-enrolled 81.1% and 82.5% of available women, respectively. Women who re-enrolled tended to have better health characteristics than those not re-enrolled. Compared to women of comparable age in the original cohort, women retained for the second posttrial follow-up less often had a history of cardiovascular disease (odds ratio (OR) = 0.36), hypertension (OR = 0.57), diabetes (OR = 0.59), or measured cognitive deficit (OR = 0.40). These women more often had graduated from high school (OR = 1.72) and had participated in other WHI trials (OR = 1.76).

Limitations

We have examined experience with creating follow-up cohorts from participants in a single study. Thus, our findings may not apply to other cohorts and protocols.

Conclusions

Posttrial enrollment in follow-up studies can be successful; however, the characteristics of the resulting cohort may differ substantially from the originally assembled group of trial participants. Collection during the original trial of potential predictors of differential re-enrollment may strengthen interpretation of findings.

Get full access to this article

View all access options for this article.

References

Holman

Paul

Bethel

Matthews

Neil

. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–89.

Lipid Research Clinics Investigators. The lipid research clinics coronary primary prevention trial. Results of 6 years post-trial follow-up. Arch Intern Med 1992; 152(7): 1399–410.

Jong

Yusuf

Rousseau

Ahn

Bangdwala

. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study. Lancet 2003; 361(9372): 1843–48.

Holman

Paul

Bethel

Neil

Matthews

. Long-term follow-up after tight blood pressure control in type 2 diabetes. N Engl J Med 2008; 359(15): 1565–76.

Patel

Kostis

Wilson

. Long-term fatal outcomes in subjects with stroke or transient ischemic attack: Fourteen-year follow-up of the Systolic Hypertension in the Elderly Program. Stroke 2008; 39(4): 1084–89.

EDIC Study Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999; 48(2): 383–90.

Nathan

Lachin

Cleary

. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N Engl J Med 2003; 348(23): 2349–52.

Haywood

Ford

Crow

. Atrial fibrillation at baseline and during follow-up in ALLHAT. J Am Coll Cardiol 2009; 54(22): 2023–31.

Appel

Wright

Greene

. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363(10): 918–29.

10.

The DREAM Trial Investigators. Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care 2011; 34(6): 1265–69.

11.

Hodis

Mack

LaBree

. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128(23): 262–69.

12.

Espeland

O’Leary

Terry

. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005; 6(1): 3.

13.

Lovato

Hill

Hertert

Hunninghake

Probstfield

. Recruitment for controlled clinical trials: Literature summary and annotated bibliography. Control Clin Trials 1997; 18(4): 328–57.

14.

Wyatt

Diekelmann

Henderson

. A community-driven model of research participation: The Jackson Heart Study Participant Recruitment and Retention Study. Ethn Dis 2003; 13: 438–55.

15.

Stefanick

Cochrane

Hsia

. The Women’s Health Initiative postmenopausal hormone trials: Overview and baseline characteristics of participants. Ann Epidemiol 2003; 13(9 Suppl): S78–S86.

16.

Sturmer

Glynn

Lee

I-M

. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physician’s Health Study. Ann Intern Med 1998; 128(9): 713–20.

17.

de Boer

Rue

Cleary

. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria. Arch Intern Med 2011; 171(5): 412–20.

18.

Lanza

Murphy

. The polyp prevention trial continued follow-up study: No effect of a low-fat, high-fiber, high-fruit and – vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev 2007; 16(9): 1745–52.

19.

The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19(1): 61–109.

20.

Jackson

LaCroix

Cauley

. The Women’s Health Initiative calcium-vitamin D trial: Overview and baseline characteristics of participants. Ann Epidemiol 2003; 13(9 Suppl): S98–S106.

21.

Ritenbaugh

Patterson

Chlebowski

. The Women’s Health Initiative Dietary Modification trial: Overview and baseline characteristics of participants. Ann Epidemiol 2003; 13(9 Suppl): S87–S97.

22.

Shumaker

Reboussin

Espeland

. The Women’s Health Initiative Memory Study: A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 1998; 19(6): 604–21.

23.

Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–33.

24.

The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogens in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701–12.

25.

De Groot

Beckerman

Lankhorst

. How to measure co-morbidity: A critical review of available methods. J Clin Epidemiol 2003; 56(3): 221–29.

26.

Teng

Chui

. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987; 48(8): 314–18.

27.

Rapp

Espeland

Hogan

Jones

Dugan

. Baseline experience with the Modified Mini-Mental State Exam: The Women’s Health Initiative Memory Study (WHIMS). Aging Ment Health 2003; 7(3): 217–23.

28.

LaCroix

Chlebowski

Manson

. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 2011; 305(13): 1305–14.

29.

Chlebowski

Anderson

Glass

. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304(15): 1684–92.

30.

Brunner

Aragaki

Barnabei

. Menopausal symptom experience before and after stopping estrogen therapy in the Women’s Health Initiative randomized placebo-controlled trial. Menopause 2010; 17(5): 946–54.

31.

Resnick

Espeland

Jaramillo

. Effects of postmenopausal hormone therapy on regional brain volumes in older women: The Women’s Health Initiative Magnetic Resonance Imaging Study (WHIMS-MRI). Neurology 2009; 72(2): 135–42.

32.

Espeland

Tindle

Bushnell

. Regional brain and ischemic lesion volumes in women with cognitive impairment following exposure to conjugated equine estrogen therapies: The Women’s Health Magnetic Resonance Imaging Study (WHIMS-MRI). J Gerontol Med Sci 2009; 64A(12): 1243–50.

33.

Shumaker

Legault

Kuller

. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004; 291(24): 2947–58.

34.

National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. The National Academic Press, Washington, DC, 2010.